氨甲酰胆碱(Carbamylcholine)对大鼠缺血心室致颤阈值的影响及其与cAMP、cGMP的关系

本实验以心室颤动阈(VFT)作为心室易颤性的指标,观察胆碱类物质氨甲酰胆碱对大鼠缺血心室 VFT 的影响及其与心肌 cAMP 和 cGMP 水平的关系。实验结果表明,氨甲酰胆碱可提高正常心脏和急性局部缺血心脏的 VFT,提高缺血和未缺血心肌的 cGMP 水平,但明显降低缺血心肌 cAMP 水平,使缺血和未缺血心肌的 cAMP/cGMP 比值显著降低,其作用与肾上腺素正好相反。实验结果还表明,急性局部缺血心脏的 VFT 与缺血心肌 cAMP/cGMP 比值之间有密切的负相关关系,相关系数 r=-0.905(n=22,P<0.001)。上述结果提示缺血心肌 cAMP/cGMP 比值的提高可能是急性心肌梗塞早期发生心室纤维性颤动的重要因素。     

己酮可可碱对肺纤维化大鼠MMP-2和TIMP-1表达的影响

目的观察己酮可可碱(pentoxifylline, PTX)对博来霉素致肺纤维化大鼠肺组织基质金属蛋白酶2(matrix metalloproteinase-2)和基质金属蛋白酶组织抑制剂1(tissue inhibitor of matrix metalloproteinase-1)表达的影响,初步探讨其抗肺纤维化的作用机制.方法 SD大鼠36只,随机分为模型组、治疗组和对照组.模型组和治疗组气管内注射博来霉素诱导肺纤维化,对照组在相同条件下给予生理盐水.第二天起治疗组大鼠腹腔给予己酮可可碱6mg/kg.d,其余两组相同条件下给予生理盐水.治疗的第7d和28d,处死动物取出肺组织,用RT-PCR和免疫组化ABC法观察各组鼠肺组织MMP-2和TIMP-1表达的变化. 结果与模型组比较,治疗组经PTX作用的第7d和28d肺组织中MMP-2和TIMP-1 mRNA的基因转录均有减少,MMP-2 mRNA表达分别降低33.4%和35.5%(P＜0.001),TIMP-1 mRNA表达分别降低25.3%和33.0%(P＜0.05).免疫组化结果则显示,PTX作用的第7d和28dMMP-2分别较模型组降低30.7%和41.7%(P＜0.05),TIMP-1分别降低13.1%和19.8%(P＜0.05).结论 PTX对肺纤维化不同时期肺组织中MMP-2和TIMP-1的表达均有一定程度的降低作用,其可能通过调整MMP-2和TIMP-1比值使其趋于平衡,从而延缓甚至抑制纤维化的进程.     

慢性缺氧对大鼠肺动脉内皮依赖性舒张反应及cGMP含量的影响

本实验观察了慢性缺氧对大鼠肺动脉内皮依赖性舒张反应和肺动脉内环磷酸鸟苷(cGMP)含量的影响。乙酰胆碱(ACh)和三磷酸腺苷(ATP)可使正常大鼠的离体肺动脉产生内皮依赖性舒张反应,其舒张作用不受消炎痛的影响,但被甲烯蓝完全抑制。慢性缺氧明显减低了 ACh 和 ATP 诱发的大鼠肺内和肺外动脉的内皮依赖性舒张反应。当 ACh 浓度为10~(-6)mol/L 时,缺氧组大鼠肺内和肺外动脉舒张百分数分别为对照组的61.3%和59.2%;当 ATP浓度为1.8×10~(-5)mol/L 时,缺氧组大鼠肺内和肺外动脉舒张反应分別为对照组的64.9%和55.3%。慢性缺氧也减低了硝普钠(SNP)诱发的大鼠肺动脉非内皮依赖性舒张反应。慢性缺氧显著减低了大鼠肺动脉内 cGMP 的含量。缺氧组和对照组大鼠肺动脉内 cGMP 的基础含量分别是51.9±5.7 pmol/g wet wt.(n=14)和84.9±9.7 pmol/g wet wt.(n=14),p<0.01;经 10~(-7)mol/L ACh 刺激后分别是91.4±7.3 pmol/g wet wt.(n=5)和240.8±30.6pmol/g wet wt.(n=5),p<0.01。慢性缺氧可能抑制了肺动脉平滑肌细胞胞浆中可溶性鸟苷酸环化酶,从而减低了肺动脉对内皮舒张因子和 SNP 的舒张反应性。     

银杏叶提取物抗实验性血栓模型大鼠的作用及机制

目的:研究银杏叶提取物对血栓模型大鼠血栓形成,血小板聚集及血浆中一氧化氮(NO),环磷酸鸟苷(cGMP)和前列环素(PGI2)的影响.方法:100只SD雄性大鼠随机分为5组,分别ig给予5gL-1的CMC-Na,100mg.Kg-1阿司匹林(Asp),42,21,10.5mg.Kg-1银杏叶提取物连续4w.建立大鼠动静脉旁路血栓模型,观察药物时血栓形成的影响,比浊法观察对ADP诱导的血小板聚集的作用,按试剂盒方法检测药物对血浆中NO,cGMP,PGI2的影响.结果:银杏叶提取物可显著抑制血栓形成和血小板聚集率,升高血浆中NO,cGMP,PGI2浓度,高剂量组效果优于阿司匹林组.结论:银杏叶提取物具有抗血栓作用.     

甘草甜素对肾脏转化生长因子β1作用的实验研究

目的:探讨甘草甜素对肾小球硬化模型中转化生长因子β1(TGFβ1)作用.方法:采用尾静脉注射阿霉素方法建立大鼠肾小球硬化模型.实验随机分为模型组、治疗组和对照组.检测各组第4和8周各项指标的变化.包括①24h尿蛋白定量,血尿素氮(BUN)、肌酐(Scr)、胆固醇(Cho)和白蛋白(Alb).②各组肾皮质进行光镜等病理学检测.③应用免疫组织化学方法检测肾组织内转化生长因子β1(TGFβ1)蛋白质的表达.④采用标准曲线法进行荧光定量PCR检测肾组织内TGFβ1 mRNA的表达.结果:①治疗组与模型组相比较,24h尿蛋白定量、BUN、Scr、Cho和Alb均有不同程度改善(p<0.05).②肾皮质病理学改变肾小球硬化程度治疗组明显轻于模型组.③肾组织内TGFβ1蛋白和mRNA表达治疗组与模型组比较表达峰值均有不同程度降低(p<0.05).结论:从蛋白和mRNA水平同时证实甘草甜素对TGFβ1蛋白和mRNA的表达有明显的抑制作用,对大鼠肾小球硬化有早期保护作用,为临床应用提供了依据.     

蝉蜕、僵蚕对大鼠系膜增生性肾炎作用的实验研究

目的:研究蝉蜕、僵蚕对大鼠系膜增生性肾小球肾炎(MsPGN)的治疗作用。方法:采用改良慢性血清病法制备的MsPGN模型,随机分为模型对照组、蝉蜕高剂量组、蝉蜕低剂量组、僵蚕高剂量组、僵蚕低剂量组,另设正常对照组。分别在用药5周、8周后检测大鼠24h尿蛋白;8周后处死大鼠,行血液生化指标检测和肾组织HE染色观察,免疫组化法检测TGF-β1的表达水平。结果:与模型对照组比较,用药5周后蝉蜕、僵蚕高剂量组显著降低大鼠24h蛋白尿(P<0.01);8周后各治疗组大鼠肾组织TGF-β1表达量,24h蛋白尿和血清胆固醇均显著下降,蝉蜕高、低剂量组血清白蛋白均有所升高,差异具有显著性意义(P<0.01)。肾组织形态学观察显示,蝉蜕、僵蚕高剂量组个别区域肾小球系膜细胞轻度增生,系膜区轻度增宽,管腔无挤压现象,较模型组明显改善。结论:蝉蜕、僵蚕均能有效降低MsPGN大鼠24h尿蛋白,改善脂质代谢,其作用机制可能与抑制TGF-β1的过度表达有关。     

α-黑色素细胞刺激素对白细胞介素-1β发热的解热机理研究

本研究观察了α－黑色素细胞刺激素（α－ＭＳＨ）对家兔白细胞介素－１β（ＩＬ－１β）发热效应及下丘脑组织腺苷环－磷酸（ｃＡＭＰ）含量的影响;同时观察了下丘本外培养过程中,α－ＭＳＨ对ＩＬ－１β刺激下丘脑释放ｃＡＭＰ的影响。结果显示：α－ＭＳＨ能显著降低ＩＬ－１β引起的体温升高（Ｐ〈０．０５）;同时抑制下丘脑组织ｃＡＭＰ含量的增高（Ｐ〈０．０１）。ＩＬ－１β与下丘脑组织培养,其上清液的ｃＡＭＰ含量明显     

黄芪对白介素1β诱导的大鼠系膜细胞增殖和细胞外基质产生的影响

目的:观察黄芪(Astragalus Membranaceus,AM)注射剂对5/6肾切除大鼠模型的疗效,及体外对系膜细胞(Mesangial cells,MCs)增殖和细胞外基质(Intracellular Matrix,ECM)产生的影响。方法:建立5/6肾切除大鼠模型后,将大鼠分为四组:对照组、未治疗组、低剂量/高剂量AM治疗组。观察比较16周后各组大鼠肾功能和尿蛋白排泄量情况。体外以白介素1β(IL-1β)作为刺激物,诱导MCs增殖,给予不同剂量AM干预。二苯基四氮唑溴盐(MTT)法检测MCs增殖情况,流式细胞仪检测细胞周期,酶联免疫吸附(ELISA)法检测细胞上清中纤连蛋白(fibronectin)含量,RT-PCR检测细胞p38 mRNA表达,Western免疫印迹法检测胶原Ⅳ、总p38MAPK、磷酸化p38MAPK、磷酸化MKK3/MKK6、磷酸化MKK4等蛋白水平。结果:在体外AM可显著抑制IL-1β诱导的MCs增殖和阻止细胞进入合成周期,显著降低fibronectin、胶原Ⅳ产生,磷酸化p38蛋白和磷酸化MKK3/MKK6的表达显著受抑;在体内AM治疗能显著改善5/6肾切除大鼠的肾功能情况,降低蛋白尿排泄量,延缓肾功能恶化。结论:AM治疗可通过抑制磷酸化MKK3/6和磷酸化p38 MAPK蛋白的表达,发挥抑制IL-1β诱导的MCs增殖作用,能抑制MCs的ECM积聚,有效的治疗进展性肾脏病,为慢性肾纤维化提供了有前景的治疗策略。     

骨化三醇对系膜增生性肾炎大鼠TGF-β1的影响

目的：探讨骨化三醇对系膜增生性肾小球肾炎模型大鼠TGF-β1的作用。方法：应用抗大鼠胸腺细胞免疫血清（Anti-thy-mocyte serum,A TS）抗体一次性尾静脉注射复制大鼠MsPGN模型,将实验大鼠分为三组对照组（A组）、模型组（B组）、骨化三醇治疗组（c组）,分别与1、3、7、14天每组各处死6只大鼠,进行PAS染色,分析肾皮质损伤程度,采用ELISA法检测TGF-β1在血清中的变化,Envision免疫组化法检测TGF-β1在肾小球中的表达情况。结果：肾炎组大鼠血清及肾小球中TGF-β1表达明显高于对照组（p〈0.01）;骨化三醇治疗组大鼠血清及肾小球中TGF-β1的表达明显显著减轻（p〈0.01）。结论：骨化三醇可以抑制MsPGN模型大鼠中TGF-β1的表达,从而早期延缓肾小球疾病纤维化的发展。     

内皮素—1对大鼠排卵前卵泡颗粒细胞产生孕酮的影响

本文用离体细胞体外孵育法研究了内皮素－１（ＥＴ）对大鼠排卵前卵泡颗粒细胞孕酮生成的影响及其作用机理。结果发现,ＥＴ能显著抑制ｈＣＧ刺激下的孕酮产生,抑制作用在浓度为１０－８ｍｏｌ／Ｌ时,即有显著意义（Ｐ＜０．０５,ｎ＝６）,至１０－７ｍｏｌ／Ｌ时则有非常显著的意义（Ｐ＜０．０１,ｎ＝６）;不同浓度ＥＴ（１０－７—１０－７ｍｏｌ／Ｌ）,对颗粒细胞基础孕酮的产生无明显影响。进一步研究表明,ＥＴ对ｈＣＧ刺激下孕酮生成的抑制作用,在用免抗人内皮素抗血清（ＥＴ－Ａ）１：１０００及ｃＡＭＰ后能明显被逆转。实验中还观察到,ＥＴ使颗粒细胞ＬＨ／ｈＣＧ受体数下降,亲和力降低。本文结果提示,ＥＴ可能为卵巢内的一种局部调节肽,通过作用于ＥＴ受体,干扰ＬＨ／ｈＣＧ受体功能和ｃＡＭＰ生成而抑制颗粒细胞孕酮的产生。     

BAY 41-2272 activates host defence against local and disseminated Candida albicans infections

In our previous study, we have found that 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-4-ylamine (BAY 41-2272), a guanylate cyclase agonist, activates human monocytes and the THP-1 cell line to produce the superoxide anion, increasing in vitro microbicidal activity, suggesting that this drug can be used to modulate immune functioning in primary immunodeficiency patients. In the present work, we investigated the potential of the in vivo administration of BAY 41-2272 for the treatment of Candida albicans and Staphylococcus aureus infections introduced via intraperitoneal and subcutaneous inoculation. We found that intraperitoneal treatment with BAY 41-2272 markedly increased macrophage-dependent cell influx to the peritoneum in addition to macrophage functions, such as spreading, zymosan particle phagocytosis and nitric oxide and phorbol myristate acetate-stimulated hydrogen peroxide production. Treatment with BAY 41-2272 was highly effective in reducing the death rate due to intraperitoneal inoculation of C. albicans, but not S. aureus. However, we found that in vitro stimulation of peritoneal macrophages with BAY 41-2272 markedly increased microbicidal activities against both pathogens. Our results show that the prevention of death by the treatment of C. albicans-infected mice with BAY 41-2272 might occur primarily by the modulation of the host immune response through macrophage activation.     

Binding of YC-1/BAY 41-2272 to soluble guanylate cyclase: A new perspective to the mechanism of activation

Soluble guanylate cyclase (sGC), a heterodimeric heme protein, catalyses the conversion of GTP in to cyclic GMP, which acts as a second messenger in cellular signaling. Nitric oxide activates this enzyme several hundred folds over its basal level. Carbon monoxide, along with some activator molecules like YC-1 and BAY, also synergistically activate sGC. Mechanism of this synergistic activation is a matter of debate. Here we review the existing literature to identify the possible binding site for YC-1 and BAY on bovine lung sGC and its mechanism of activation. These two exogenous compounds bind sGC on α subunit inside a pocket and thus exert allosteric effect via subunit interface, which is relayed to the catalytic site. We used docking studies to further validate this hypothesis. We propose that the binding of YC-1/BAY inside the sensory domain of the α subunit modulates the interactions on the subunit interface resulting in rearrangements in the catalytic site into active conformation and this partly induces the cleavage of Fe-His bond.     

BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase

Soluble guanylyl cyclase is an important target for endogenous nitric oxide and the guanylyl cyclase modulator, YC-1. Recently BAY 41-2272 was identified as a similar but more potent and more specific substance. While YC-1 also acts as non-specific phosphodiesterase inhibitor, BAY 41-2272 is devoid of an effect on phosphodiesterases. BAY 41-2272 has so far only been tested on the alpha(1)/beta(1) heterodimeric isoform of soluble guanylyl cyclase and its binding site has been mapped to a region in the alpha(1) subunit amino-terminal sequence. Although this region is poorly conserved in the alpha(2) subunit, we show in the current study that the alpha(2)/beta(1) heterodimeric enzyme isoform is activated by BAY 41-2272. Deletion analysis of the alpha(2) subunit and co-expression with the beta(1) subunit in the baculovirus/Sf9 system is consistent with the amino-terminal amino acids 104 to 401 of the alpha(2) subunit as binding site for BAY 41-2272.     

A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway

We have established a rapid, homogeneous, cell-based, and highly sensitive assay for guanosine 3'-5'-cyclic monophosphate (cGMP) that is suitable for fully automated ultra-high-throughput screening. In this assay system, cGMP production is monitored in living cells via Ca2+ influx through the olfactory cyclic nucleotide-gated cation channel CNGA2, acting as the intracellular cGMP sensor. A stably transfected Chinese hamster ovary (CHO) cell line was generated recombinantly expressing soluble guanylate cyclase, CNGA2, and aequorin as a luminescence indicator for the intracellular calcium concentration. This cell line was used to screen more than 900,000 compounds in an automated ultra-high-throughput screening assay using 1536-well microtiter plates. In this way, we have been able to identify BAY 58-2667, a member of a new class of amino dicarboxylic acids that directly activate soluble guanylate cyclase. The assay system allows the real-time cGMP detection within living cells and makes it possible to screen for activators and inhibitors of enzymes involved in the nitric oxide/cGMP pathway.     

Identification of residues crucially involved in soluble guanylate cyclase activation

The ubiquitous heterodimeric nitric oxide (NO) receptor soluble guanylate cyclase (sGC) plays a key role in various signal transduction pathways. Binding of NO takes place at the prosthetic heme moiety at the N-terminus of the beta(1)-subunit of sGC. The induced structural changes lead to an activation of the catalytic C-terminal domain of the enzyme and to an increased conversion of GTP into the second messenger cyclic GMP (cGMP). In the present work we selected and substituted different residues of the sGC heme-binding pocket based on a sGC homology model. The generated sGC variants were tested in a cGMP reporter cell for their effect on the enzyme activation by heme-dependent (NO, BAY 41-2272) stimulators and heme-independent (BAY 58-2667) activators. The use of these experimental tools allows the enzyme's heme content to be explored in a non-invasive manner. Asp(44), Asp(45) and Phe(74) of the beta(1)-subunit were identified as being crucially important for functional enzyme activation. beta(1)Asp(45) may serve as a switch between different conformational states of sGC and point to a possible mechanism of action of the heme dependent sGC stimulator BAY 41-2272. Furthermore, our data shows that the activation profile of beta(1)IIe(145) Tyr is unchanged compared to the native enzyme, suggesting that Tyr(145) does not confer the ability to distinguish between NO and O(2). In summary, the present work further elucidated intramolecular mechanisms underlying the NO- and BAY 41-2272-mediated sGC activation and raises questions regarding the postulated role of Tyr(145) for ligand discrimination.     

Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing

A reversed-phase (RP) high-performance liquid chromatographic (HPLC) method with fluorescence detection allowing the sensitive and specific quantification of BAY 12-8039, a new antimicrobially active 8-methoxyquinolone, in biological fluids is described. The method is compared to a microbiological assay (bioassay) based on B. subtilis test strain with a limit of quantification of approximately 60 μg/l. Following dilution and centrifugation, plasma, saliva or urine supernatant is directly injected onto the HPLC system. Concentrations down to a limit of quantification of 2.5 μg/l can be quantified in plasma, saliva and urine. Data on recovery, accuracy and precision of the method throughout the whole working range as well as results on stability of the analyte are presented. The concentration data are correlated with results from the bioassay. BAY 12-8039 is stable in plasma after repeated freeze-thaw cycles and following storage at −20°C for at least 12 months. The results of HPLC measurements excellently agree with bioassay data indicating the relevance of the method as a tool in clinical development to answer pharmacokinetic questions related to antimicrobial activity. The method was applied to human plasma, saliva and urine from subjects after a single oral dose of 400 mg of BAY 12-8039.     

Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus

Nitric oxide (NO)-cGMP signaling plays a critical role during the transition of the pulmonary circulation at birth. BAY 41-2272 is a novel NO-independent direct stimulator of soluble guanylate cyclase that causes vasodilation in systemic and local circulations. However, the hemodynamic effects of BAY 41-2272 have not been studied in the perinatal pulmonary circulation. We hypothesized that BAY 41-2272 causes potent and sustained fetal pulmonary vasodilation. We performed surgery on 14 fetal lambs (125-130 days gestation; term = 147 days) and placed catheters in the main pulmonary artery, aorta, and left atrium to measure pressures. An ultrasonic flow transducer was placed on the left pulmonary artery (LPA) to measure blood flow, and a catheter was placed in the LPA for drug infusion. Pulmonary vascular resistance (PVR) was calculated as pulmonary artery pressure minus left atrial pressure divided by LPA blood flow. BAY 41-2272 caused dose-related increases in pulmonary blood flow up to threefold above baseline and reduced PVR by 75% (P < 0.01). Prolonged infusion of BAY 41-2272 caused sustained pulmonary vasodilation throughout the 120-min infusion period. The pulmonary vasodilator effect of BAY 41-2272 was not attenuated by N(omega)-nitro-l-arginine, a NO synthase inhibitor. In addition, compared with sildenafil, a phosphodiesterase 5 inhibitor, the pulmonary vasodilator response to BAY 41-2272 was more prolonged. We conclude that BAY 41-2272 causes potent and sustained fetal pulmonary vasodilation independent of NO release. We speculate that BAY 41-2272 may have therapeutic potential for pulmonary hypertension associated with failure to circulatory adaptation at birth, especially in the setting of impaired NO production.     

双抗体夹心ELISA检测HIV-1 gp41抗原方法的建立

目的:建立检测HIV-1gp41抗原的双抗体夹心ELISA,并探讨其临床应用的可行性。方法:用饱和硫酸铵(SAS)纯化抗HIV-1gp41-5单克隆抗体(mAb),用HRP标记后建立双抗体夹心ELISA法,对其灵敏度及特异性进行检测,并用该方法对40份HIV-1阳性血清进行了检测。结果:用mAbE12(5μg/mL)为包被抗体,2H6为酶标记抗体(1∶900)建立了双抗体夹心ELISA法,检测gp41-5多肽的灵敏度是100pg/mL。对HIV-1阳性血清中gp41抗原的检出率为67.5%(27/40)。结论:建立了特异性强、灵敏度良好的检测HIV-1gp41抗原的双抗体夹心ELISA法。     

Split Gp41-1 intein splicing as a model to evaluate the cellular location of the oncosuppressor Maspin in an in vitro model of osteosarcoma

Inteins are proteins involved in the protein splicing mechanism, an autoprocessing event, where sequences (exteins) separated by inteins become ligated each other after recombination. Two kinds of inteins have been described, contiguous inteins and split inteins. The former ones are transcribed and translated as a single peptide along with their exteins, while the latter are fragmented between two different genes and are transcribed and translated separately. The aim of this study is to establish a method to obtain a fluorescent eukaryotic protein to analyze its cellular localization, using the natural split gp41-1 inteins. We chose natural split inteins due to their distribution in all three domains of life. Two constructs were prepared, one containing the N-terminal split intein along with the N-moiety of the Red Fluorescent Protein (RFP) and a second construct containing the C-terminal of split intein, the C-moiety of RFP and the gene coding for Maspin, a tumor suppressor protein. The trans-splicing was verified by transfecting both N-terminal and C-terminal constructs into mammalian cells. The success of the recombination event was highlighted through the fluorescence produced by reconstituted RFP after recombination, along with the overlap of the red fluorescence produced by recombined RFP and the green fluorescence produced by the hybridization of the recombinant Maspin with a specific antibody. In conclusion, we opted to use this mechanism of recombination to obtain a fluorescent Maspin instead to express a large fusion protein, considering that it could interfere with Maspin's structure and function.     

Protective Role of Probiotic Lactic Acid Bacteria Against Dietary Fumonisin B1-induced Toxicity and DNA-Fragmentation in Sprague-Dawley Rats

The genus Fusarium, especially F. verticillioides and F. proliferatum, has been found in several agricultural products worldwide, especially in maize. Regardless the occurrence of symptoms, the presence of Fusarium in maize constitutes an imminent risk due to its ability to produce fumonisins, mycotoxins with proven carcinogenic effect on rats, swine, and equines and already classified as possible carcinogens to humans. The toxicity of incremental levels of fumonisin B1 (FB1), that is, 50, 100, and 200 mg FB1/kg diet, and the role of Lactobacillus delbrueckii subsp. lactis DSM 20076 (LL) and Pediococcus acidilactici NNRL B-5627 (PA) supplementation in counteracting the FB1 effects in intoxicated rats were monitored over a period of 4 weeks. Effects on the feed intake and body weight gain were noticed. A significant (p ≤ 0.05) increase in the level of liver and kidney functions markers and DNA fragmentation was also noticed in rat groups T100 and T200. The lactic acid bacteria (LAB) supplementation could bring back the normal serum biochemical parameters in rats fed on fumonisin B1-contaminated diets (T50 and T100) compared to FB1-treated groups. In rats of high-dosage dietary groups supplemented with LAB (T200-LL and T200-PA), the supplementation reduced the serum activity levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and creatinine by 11.3, 11.9, 32, and 20%, respectively. DNA fragmentations were observed in the rat group treated with 200 mg FB1 after 3 weeks, while fragmentation was noticed in treated groups with 100 and 200 mg FB1 after 4 weeks. No DNA fragmentation was apparent in FB1-treated rats co-administered the LL or PA strain. These results suggest that in male rats consuming diets containing FB1, there is a time- and dose-dependent increase in serum enzyme activities and DNA lesions. Moreover, Lb. delbrueckii subsp. lactis (LL) and P. acidilactici (PA) strains have a protective effect against antigenotoxicity and precancerous lesions.